article thumbnail

Intermediate and long-term residual cardiovascular risk in patients with established cardiovascular disease treated with statins

Frontiers in Cardiovascular Medicine

Methods This narrative review examines the contemporary literature assessing intermediate- and long-term event rates in patients with established CV disease treated with statins. Recurrent stroke occurs in up to 19% of patients seven years after a first cerebrovascular event.

article thumbnail

Lipoprotein(a) as a risk factor for atherosclerotic cardiovascular disease in patients in non-metropolitan area of Brandenburg, Germany

Frontiers in Cardiovascular Medicine

Results Brandenburg patients with cardiovascular diseases showed higher Lp(a) levels than healthy controls (24.2% vs. 14.8%, p  = 0.001), and the high-Lp(a) group demonstrated a higher prevalence of coronary artery disease, peripheral artery disease, or cerebrovascular disease than the low-Lp(a) group ( p  = 0.004).

article thumbnail

CorVascular’s VasoGuard Earns FDA 510(k) Clearance

DAIC

mtaschetta-millane Mon, 07/29/2024 - 09:16 July 29, 2024 — CorVascular , a leading producer of peripheral arterial disease (PAD) / peripheral vascular disease (PVD) testing devices, today announced the U.S. Food and Drug Administration (FDA) has cleared its VasoGuard V-Series as Class II medical devices.

article thumbnail

Epidemiology of atherosclerotic cardiovascular disease in polygenic hypercholesterolemia with or without high lipoprotein(a) levels

Frontiers in Cardiovascular Medicine

Background and aims Epidemiology of atherosclerotic cardiovascular disease might be different in patients with polygenic hypercholesterolemia plus high levels (≥30 mg/dl) of Lp(a) (H-Lpa) than in those with polygenic hypercholesterolemia alone (H-LDL).

article thumbnail

Lowering Atherosclerotic Cardiovascular Disease Events by Treating Residual Inflammatory Risk

DAIC

Atherosclerotic cardiovascular disease (ASCVD), caused by plaque buildup in arterial walls, is one of the leading causes of disability and death worldwide.1,2 1,2 ASCVD causes or contributes to conditions that include coronary artery disease (CAD), cerebrovascular disease, and peripheral vascular disease (inclusive of aortic aneurysm).3